Dapagliflozin effective but more bladder and breast cancers observed
This article was originally published in Scrip
Executive Summary
Dapagliflozin, filed with US and European regulatory authorities earlier this year, was effective in sustaining blood sugar levels and weight loss in type 2 diabetes patients in a two-year study, say developers Bristol-Myers Squibb and AstraZeneca. However, more bladder and breast cancers have been observed in patients treated with the diabetes drug.